<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961115</url>
  </required_header>
  <id_info>
    <org_study_id>CITN-04</org_study_id>
    <secondary_id>NCI-2013-01605</secondary_id>
    <secondary_id>CITN-04</secondary_id>
    <secondary_id>CITN-04</secondary_id>
    <secondary_id>U01CA154967</secondary_id>
    <nct_id>NCT01961115</nct_id>
  </id_info>
  <brief_title>Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma</brief_title>
  <official_title>A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating&#xD;
      patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens&#xD;
      may help the body build an effective immune response to kill tumor cells. Giving epacadostat&#xD;
      with vaccine therapy may be an effective treatment for advanced melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the extent to which a regimen of INCB024360 (epacadostat) that normalizes&#xD;
      serum kynurenine (Kyn)/ tryptophan (Trp) ratios alters the tumor microenvironment of&#xD;
      melanoma, including determining the number and character of tumor-infiltrating lymphocytes as&#xD;
      determined by examination of serial biopsies with immunohistochemistry (IHC) and gene&#xD;
      signatures.&#xD;
&#xD;
      II. To determine the extent to which continued INCB024360 treatment plus the addition of the&#xD;
      multipeptide melanoma vaccine, MELITAC 12.1 (MELITAC 12.1 peptide vaccine), further alters&#xD;
      the tumor microenvironment of melanoma, including determining the number and character of&#xD;
      tumor-infiltrating lymphocytes as determined by serial biopsies evaluating IHC and gene&#xD;
      signatures.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether a regimen of INCB024360 that normalizes serum Kyn/Trp ratios plus&#xD;
      MELITAC 12.1 vaccine changes the level or character of the vaccine-induced clusters of&#xD;
      differentiation (CD) 8+ and CD4+ T-cell immune responses as measured in peripheral blood, as&#xD;
      compared to prior published experience.&#xD;
&#xD;
      II. To evaluate the extent to which INCB024360 plus MELITAC 12.1 vaccine alters the number&#xD;
      and character of peripheral blood mononuclear cell (PBMC) populations, including T and&#xD;
      natural killer (NK) cells, as evaluated by multiparameter flow cytometry.&#xD;
&#xD;
      III. To evaluate the extent to which INCB024360 plus MELITAC 12.1 vaccine alters the PBMC&#xD;
      transcriptome.&#xD;
&#xD;
      IV. To assess the safety and tolerability of INCB024360 plus MELITAC 12.1 vaccine.&#xD;
&#xD;
      V. To obtain preliminary data on the tumor response rate of INCB024360 plus MELITAC 12.1&#xD;
      vaccine by objective response rate (ORR), time to tumor progression, and overall survival.&#xD;
&#xD;
      VI. To associate any observed changes with the expression of IDO1 protein by IHC in tumor or&#xD;
      tumor-infiltrating cells.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive epacadostat orally (PO) twice daily (BID) on days 1-98 and receive MELITAC&#xD;
      12.1 peptide vaccine intradermally (ID)/subcutaneously (SC) on days 21, 28, 35, 56, 77, and&#xD;
      98. Treatment with epacadostat may repeat every 98 days for up to 3 additional courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2013</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios.</measure>
    <time_frame>Baseline to up to day 21</time_frame>
    <description>Immunohistochemistry: Tumors were assessed by IHC for pattern of T-cell distribution and infiltration of cells expressing CD3 and CD8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios in Combination With MELITAC 12.1</measure>
    <time_frame>Day 21 up to Day 42</time_frame>
    <description>Immunohistochemistry: Tumors (day 21 &amp; day 42) were assessed by IHC for pattern of T-cell distribution and infiltration of cells expressing CD3 and CD8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PBMC Transcriptome_v2</measure>
    <time_frame>Baseline to up to 16 week</time_frame>
    <description>Analysis of PBMC gene signature. This may be compared to immunologic response, tumor biopsy data and clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Number and Character of PBMC Populations, Including T and NK Cells, as Evaluated by Multiparameter Flow Cytometry_v2</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Expression of IDO1 Protein by IHC in Tumor or Tumor-infiltrating Cells_v2</measure>
    <time_frame>Baseline to up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Level or Character of the Vaccine-induced CD8+ and CD4+ Specific T-cell Immune Responses by IFN-gamma ELISPOT_v2</measure>
    <time_frame>Baseline to up to 16 weeks</time_frame>
    <description>Assessment of immunologic response will be based on a fold-increase measure from baseline as well as using a positivity threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0_v2</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate Using the RECIST or Immune-Related Response Criteria (irRC)_v2</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival_v2</measure>
    <time_frame>From the time measurement criteria are met for complete response or partial response until the first date that recurrent and progressive disease is objectively documented, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression Using RECIST or irRC_v2</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Mucosal Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Recurrent Uveal Melanoma</condition>
  <condition>Stage IIIA Skin Melanoma</condition>
  <condition>Stage IIIA Uveal Melanoma</condition>
  <condition>Stage IIIB Skin Melanoma</condition>
  <condition>Stage IIIB Uveal Melanoma</condition>
  <condition>Stage IIIC Skin Melanoma</condition>
  <condition>Stage IIIC Uveal Melanoma</condition>
  <condition>Stage IV Skin Melanoma</condition>
  <condition>Stage IV Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (epacadostat, MELITAC 12.1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (epacadostat, MELITAC 12.1)</arm_group_label>
    <other_name>INCB 024360</other_name>
    <other_name>INCB024360</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MELITAC 12.1 Peptide Vaccine</intervention_name>
    <description>Given ID/SC</description>
    <arm_group_label>Treatment (epacadostat, MELITAC 12.1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have malignant melanoma validated by histology or cytology; patients may&#xD;
             have had primary cutaneous, mucosal, or ocular melanoma or metastasis from an unknown&#xD;
             primary site&#xD;
&#xD;
               -  NOTE: patients must have measurable disease, defined as at least 1 lesion that&#xD;
                  can be accurately measured in at least 1 dimension (longest diameter to be&#xD;
                  recorded for non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm with&#xD;
                  conventional chest x-ray or as &gt;= 10 mm with spiral computed tomography (CT)&#xD;
                  scan, magnetic resonance imaging (MRI), or calipers by clinical exam&#xD;
&#xD;
          -  Unresectable stage III or IV validated by clinical criteria (including recurrent&#xD;
             melanoma), or patients with multiple skin/soft tissue metastases of melanoma that may&#xD;
             be resectable but are judged to have a future recurrence risk exceeding 70% (e.g.,&#xD;
             large adenopathy, distant skin metastases or multiple in-transit melanoma metastases);&#xD;
             tumor deemed amenable to biopsy (excisional, incisional, or core, with at least 100&#xD;
             mm^3 tumor volume per biopsy date) and fine-needle aspiration (FNA) biopsy&#xD;
&#xD;
               -  NOTE: optimally, patients will have tumor approachable for three serial biopsies&#xD;
                  during the trial; for patients with only one or two tumors approachable for&#xD;
                  biopsy, available tumor blocks from prior biopsies can serve as the pretreatment&#xD;
                  sample, but only if formalin-fixed tumor tissue is available and adequate to&#xD;
                  provide at least 20 unstained slides with sufficient tumor for analysis&#xD;
&#xD;
               -  NOTE: patients with unresectable advanced stage III or IV melanoma (including&#xD;
                  recurrent melanoma) are only eligible if they have failed at least one other&#xD;
                  first-line systemic therapy (other than adjuvant therapy); exceptions to this&#xD;
                  requirement are those patients who have refused and/or are ineligible for other&#xD;
                  systemic therapies&#xD;
&#xD;
               -  NOTE: v-raf murine sarcoma viral oncogene homolog B inhibitor (BRAFi) should be&#xD;
                  considered for all 'unresectable&quot; or metastatic melanoma with BRAFV600E mutation;&#xD;
                  for low burden in-transit disease patients may enter trial without prior systemic&#xD;
                  therapy&#xD;
&#xD;
                    -  Stage IV no evidence of disease (NED) is excluded by this criterion&#xD;
&#xD;
          -  Patients may have had prior systemic therapy without constraint on the number of prior&#xD;
             treatment regimens except:&#xD;
&#xD;
               -  Patients may not have had &gt; 450 mg/m^2 doxorubicin&#xD;
&#xD;
               -  Patients may not have had &gt; 3000 centigray (cGy) to fields encompassing the&#xD;
                  entire pelvis&#xD;
&#xD;
          -  Patients must not be on any other systemic therapy within the following intervals&#xD;
             before study enrollment:&#xD;
&#xD;
               -  1 week after stereotactic radiosurgery of the brain or comparable technology&#xD;
&#xD;
               -  4 weeks after cytotoxic chemotherapy or external beam radiation therapy&#xD;
&#xD;
               -  6 weeks after chemotherapy regimens including BCNU (carmustine) or mitomycin C&#xD;
&#xD;
               -  Patients who experience melanoma progression (by Response Evaluation Criteria in&#xD;
                  Solid Tumors [RECIST] 1.1 criteria) while on or after treatment with programmed&#xD;
                  cell death 1 (PD-1) or PD ligand-1 (PDL-1) antibody may enroll on this study&#xD;
&#xD;
                    -  NOTE: Patients must be off PD-1/PDL- antibody for at least 2 weeks to assess&#xD;
                       for delayed toxicity before being enrolled and receiving INCB024360;&#xD;
                       patients who are enrolled 2 weeks and up to 6 weeks after the last dose of&#xD;
                       PD-/PDL-1 antibody will enroll in cohort B and receive 100 mg BID of&#xD;
                       INCB024360; patients enrolled beyond the 6 week period after failing&#xD;
                       anti-PD-1/PDL-1 will be enrolled in cohort A; cohort A patients will receive&#xD;
                       300 mg BID of INCB024360; patients must not have active grade 2 autoimmune&#xD;
                       toxicities attributed to these antibodies at study entry&#xD;
&#xD;
               -  8 weeks after ipilimumab, other cytotoxic T-lymphocyte-associated protein 4&#xD;
                  (CTLA-4) antibody or other immunologically active antibody&#xD;
&#xD;
                    -  NOTE: Patients receiving prior CTLA-4, anti-PD1 antibody or other&#xD;
                       immunologic therapy must show evidence of normal pituitary function at&#xD;
                       baseline and must not have active grade 2 autoimmune toxicities attributed&#xD;
                       to these antibodies at study entry&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky &gt;= 70%)&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 75,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 x institutional upper limit of normal (bilirubin &lt; 3 ×&#xD;
             institutional upper limit of normal for Gilbert's syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             up to 2.5 times upper limit normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 x institutional upper limit of normal OR&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 mL/min/1.73 m^2 for patients with creatinine levels above&#xD;
             institutional normal&#xD;
&#xD;
          -  Prothrombin time (PT), international normalized ratio (INR) =&lt; 1.5 x institutional ULN&#xD;
             unless patient is therapeutically anticoagulated; if on anticoagulants, PT/INR need to&#xD;
             be within appropriate anticoagulation limits for the clinical indication; patients who&#xD;
             are receiving anticoagulants may participate in the trial if their anticoagulation can&#xD;
             be stopped safely for several days at the time of each biopsy&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH) up to 4 times ULN if thyroxine (T4) is normal&#xD;
&#xD;
          -  T4 within normal limits; if abnormal and patient is receiving thyroid replacement&#xD;
             therapy, the thyroid medication may be adjusted and the T4 may be re-tested&#xD;
&#xD;
          -  Patients must express human leukocyte antigen (HLA) -A1+, -A2+, or -A3+ (80% of&#xD;
             patients)&#xD;
&#xD;
          -  Lactate dehydrogenase (LDH) &lt; 5 × upper limits of normal&#xD;
&#xD;
               -  (NOTE: these criteria will select against patients with bulky disease and will&#xD;
                  select for patients with less disease and earlier disease)&#xD;
&#xD;
          -  Participants must not have had prior autoimmune disorders requiring cytotoxic or&#xD;
             immunosuppressive therapy, or autoimmune disorders with visceral involvement;&#xD;
             participants must not have an active or inactive autoimmune disorders (e.g.,&#xD;
             rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory&#xD;
             bowel disease, etc.); participants who are receiving therapy for an autoimmune or&#xD;
             inflammatory disease requiring these therapies are also excluded&#xD;
&#xD;
          -  The following will not be exclusionary:&#xD;
&#xD;
               -  Resolved ipilimumab associated inflammatory disease&#xD;
&#xD;
               -  The presence of laboratory evidence of autoimmune disease (e.g., positive&#xD;
                  antinuclear antibody [ANA] titer) without associated symptoms&#xD;
&#xD;
               -  Subjects with vitiligo, thyroiditis, or atopic dermatitis, but otherwise not&#xD;
                  meeting this criterion may be enrolled; individual cases can be discussed with&#xD;
                  the sponsor&#xD;
&#xD;
          -  Not likely curable with surgery alone&#xD;
&#xD;
          -  Not currently receiving therapy&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 48 hours&#xD;
             before initiating protocol therapy&#xD;
&#xD;
               -  NOTE: women of child-bearing potential and men must agree to use adequate&#xD;
                  contraception (hormonal or barrier method of birth control or abstinence) before&#xD;
                  study entry and for the duration of study participation; should a woman become&#xD;
                  pregnant or suspect she is pregnant while she or her partner is participating in&#xD;
                  this study, she should inform her treating physician immediately; men treated or&#xD;
                  enrolled on this protocol must also agree to use adequate contraception before&#xD;
                  the study, for the duration of study participation, and 4 months after completing&#xD;
                  INCB024360 and MELITAC 12.1 administration&#xD;
&#xD;
               -  NOTE: subjects are considered not of child bearing potential if they are&#xD;
                  surgically sterile, have undergone a hysterectomy, bilateral tubal ligation, or&#xD;
                  bilateral oophorectomy, or are postmenopausal; menopause is the age associated&#xD;
                  with complete cessation of menstrual cycles and menses, and implies the loss of&#xD;
                  reproductive potential; by a practical definition, the term assumes menopause&#xD;
                  after 1 year without menses with an appropriate clinical profile at the&#xD;
                  appropriate age&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN),&#xD;
             immunosuppressive therapy, or steroids within 4 weeks (6 weeks for nitrosoureas or&#xD;
             mitomycin C) before entering the study or those who have not recovered from adverse&#xD;
             events (AEs) due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Ipilimumab or other immunologically active therapy within 8 weeks of enrollment; NOTE:&#xD;
             patients who experience melanoma progression (by RECIST 1.1 criteria) while on or&#xD;
             after treatment with PD-1 or PDL-1 antibody may enroll on this study&#xD;
&#xD;
          -  Active immunosuppressive therapy, including concurrent systemic immunosuppressive&#xD;
             therapy or steroid therapy with more than 7 consecutive days of steroids within the&#xD;
             prior 4 weeks&#xD;
&#xD;
               -  The use of prednisone or equivalent &lt; 0.125 mg/kg/day (absolute maximum of 10&#xD;
                  mg/day) as replacement therapy is permitted&#xD;
&#xD;
               -  Inhaled corticosteroids are permitted&#xD;
&#xD;
          -  Cardiovascular disease that meets one of the following: congestive heart failure (New&#xD;
             York Heart Association class III or IV), active angina pectoris, or recent myocardial&#xD;
             infarction or acute coronary syndrome (within the last 6 months)&#xD;
&#xD;
          -  History of peripheral vascular disease (PVD) that has required surgical or&#xD;
             percutaneous intervention or documented PVD that requires medical management with&#xD;
             medications such as acetylsalicylic acid (ASA) + clopidogrel; patients with diabetes&#xD;
             that is not well controlled are excluded from participation; not well controlled is&#xD;
             defined as a hemoglobin (Hgb) A1C of greater than 7.5%&#xD;
&#xD;
          -  Current or history of systemic autoimmune disease requiring systemic therapy,&#xD;
             including significant autoimmunity associated with prior ipilimumab therapy or therapy&#xD;
             with antibodies to PD-1 or PD-L1&#xD;
&#xD;
          -  Cirrhosis, chronic hepatitis C virus positivity, or chronic hepatitis B infection;&#xD;
             subjects who may not tolerate immune-mediated hepatitis due to compromised hepatic&#xD;
             reserve also excluded from participation including: subjects with extensive liver&#xD;
             metastasis (as judged by the investigator); subjects who drink more than two standard&#xD;
             alcoholic beverages per day on a regular basis; subjects who consume more than 2 grams&#xD;
             of acetaminophen per day on a regular basis&#xD;
&#xD;
               -  A positive hepatitis B serology indicative of previous immunization (i.e.,&#xD;
                  hepatitis B surface antibody [HBsAb]-positive and hepatitis B core antibody&#xD;
                  [HBcAb]-negative), or a fully resolved acute hepatitis B infection is not an&#xD;
                  exclusion criterion&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents for melanoma&#xD;
&#xD;
          -  Patients who have had a grade one or grade two gastrointestinal adverse event during&#xD;
             or after receiving anti-CTLA-4, anti-PD1 or anti-PD, without a colonoscopy verifying&#xD;
             complete resolution of the adverse event&#xD;
&#xD;
          -  Patients who have experienced bowel perforation, neurologic involvement, Guillain&#xD;
             Barré syndrome, Myasthenia Gravis, Steven Johnson syndrome and other intractable&#xD;
             events or grade 4 non-laboratory toxicity&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnancy, nursing, or unwilling to take adequate birth control during therapy&#xD;
&#xD;
               -  NOTE: pregnant women are excluded from this study; breastfeeding should be&#xD;
                  discontinued if the mother is treated with INCB024360 and MELITAC 12.1&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder&#xD;
&#xD;
               -  NOTE: HIV-positive patients taking combination antiretroviral therapy are&#xD;
                  ineligible&#xD;
&#xD;
          -  Extensive active brain disease, including symptomatic brain metastases or the presence&#xD;
             of leptomeningeal disease&#xD;
&#xD;
               -  Patients with brain metastasis, after definitive therapy with surgery or&#xD;
                  stereotactic radiation and stable off steroids for &gt; 4 weeks, are eligible&#xD;
&#xD;
          -  Any malignancy that has not been in complete remission for at least 3 years&#xD;
&#xD;
               -  NOTE: patients with cured basal or squamous cell skin cancer are not excluded;&#xD;
                  patients with a history of excised in situ cancers, including breast, cervical,&#xD;
                  colon, superficial bladder, prostate or other body system are not excluded; study&#xD;
                  entry will be allowed at the discretion of the Principal Investigator&#xD;
&#xD;
               -  NOTE: recurrence of the in situ cancer or tumor at the time of study entry would&#xD;
                  be exclusionary&#xD;
&#xD;
          -  Monoamine oxidase (MAO) inhibitor use within the past 3 weeks or prior evidence of&#xD;
             serotonin syndrome&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to INCB024360, MELITAC 12.1, or other vaccine components&#xD;
&#xD;
          -  Prior organ allograft or allogeneic transplantation, if the transplanted tissue is&#xD;
             still in place&#xD;
&#xD;
          -  Medical or psychiatric illness that would, in the opinion of the investigator,&#xD;
             preclude participation in the study or the ability of patients to provide informed&#xD;
             consent for themselves&#xD;
&#xD;
          -  History of pulmonary disease such as emphysema or chronic obstructive pulmonary&#xD;
             disease (COPD), (forced expiratory volume in one second [FEV1] &gt; 60% of predicted for&#xD;
             height and age); pulmonary function tests (PFTs) are required in patients with&#xD;
             prolonged smoking history or symptoms of respiratory dysfunction&#xD;
&#xD;
          -  Use of any UDP glucuronosyltransferase 1 family, polypeptide A9 (UGT1A9) inhibitor&#xD;
             including: acitretin, amitriptyline, androsterone, cyclosporine, dasatinib,&#xD;
             diclofenac, diflunisal, efavirenz, erlotinib, estradiol (17-beta), flutamide,&#xD;
             geftinib, gemfibrozil, glycyrrhetinic acid, glycyrrhizin, imatinib, imipramine,&#xD;
             ketoconazole, lineoleic acid, mefenamic acid, mycophenolic acid, niflumic acid,&#xD;
             nilotinib, phenobarbital, phenylbutazone, phenytoin, probenecid propofol, quinidine,&#xD;
             ritonavir, Sorafenib, sulfinpyrazone, valproic acid and verapamil from screening&#xD;
             through follow-up period&#xD;
&#xD;
          -  Low-dose Coumadin (1 mg) is acceptable; however, doses that increase INR are not&#xD;
             permitted; if an alternative to Coumadin-based anticoagulants cannot be used, the INR&#xD;
             should be monitored weekly after initiation of therapy and upon discontinuation of&#xD;
             INCB024360, until INR normalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Slingluff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Immunotherapy Trials Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 7, 2018</results_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Mac Cheever</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT01961115/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with advanced melanoma were enrolled at 4 comprehensive cancer centers in the U.S. from Sept.., 2013-Jan., 2017. Patients who failed previous standard therapies for melanoma participated in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A</title>
          <description>Cohort A - Pts. enrolled &gt;6 wks after failing anti-PD-1/PDL-1 received 300 mg INCB024360 po BID every day for 98 days Cohort B - Pts. enrolled 2-6 weeks after failing anti-PD-1/PDL-1 received 100 mg INCB024360 po BID every day for 98 days All other pts. - received 300 mg po BID&#xD;
All pts received MELITAC 12.1 intradermal/subcutaneous on days 21, 28, 35, 56, 77, 98</description>
        </group>
        <group group_id="P2">
          <title>Cohort B</title>
          <description>Pts. enrolled 2-6 wks after failing anti-PD-1/PDL-1 received 300 mg INCB024360 po BID every day for 98 days Cohort B - Pts. enrolled 2-6 weeks after failing anti-PD-1/PDL-1 received 100 mg INCB024360 po BID every day for 98 days</description>
        </group>
        <group group_id="P3">
          <title>All Other Patients</title>
          <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>Pts. enrolled &gt;6 wks after failing anti-PD-1/PDL-1 INCB024360 - 300 mg po bid continuous for 98 days MELITAC 12.1 - Intradermal/subcutaneous Days 21, 28, 35, 56, 77, 98</description>
        </group>
        <group group_id="B2">
          <title>Cohort B</title>
          <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
INCB024360 - 100 mg po bid continuous for 98 days&#xD;
MELITAC 12.1 - Intradermal/subcutaneous Days 21, 28, 35, 56, 77, 98</description>
        </group>
        <group group_id="B3">
          <title>All Other Patients</title>
          <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria INCB024360 - 300 mg po bid continuous for 98 days MELITAC 12.1 - Intradermal/subcutaneous Days 21, 28, 35, 56, 77, 98</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age calculated between time of consent and date of birth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="3.5"/>
                    <measurement group_id="B3" value="60.3" spread="14.1"/>
                    <measurement group_id="B4" value="62.2" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios.</title>
        <description>Immunohistochemistry: Tumors were assessed by IHC for pattern of T-cell distribution and infiltration of cells expressing CD3 and CD8.</description>
        <time_frame>Baseline to up to day 21</time_frame>
        <population>For one subject in cohort A day 21 tumor biopsy material was not obtained (For analysis of Cohort A n = 1). For analysis of Cohort &quot;All Other Patients&quot; n = 7 due to day 21 biopsy not being obtained in 2 other subjects. In addition, for one of those subjects there was no baseline tumor biopsy obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios.</title>
          <description>Immunohistochemistry: Tumors were assessed by IHC for pattern of T-cell distribution and infiltration of cells expressing CD3 and CD8.</description>
          <population>For one subject in cohort A day 21 tumor biopsy material was not obtained (For analysis of Cohort A n = 1). For analysis of Cohort &quot;All Other Patients&quot; n = 7 due to day 21 biopsy not being obtained in 2 other subjects. In addition, for one of those subjects there was no baseline tumor biopsy obtained.</population>
          <units>Ratio: Day21CD8s/Day0CD8s</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios in Combination With MELITAC 12.1</title>
        <description>Immunohistochemistry: Tumors (day 21 &amp; day 42) were assessed by IHC for pattern of T-cell distribution and infiltration of cells expressing CD3 and CD8.</description>
        <time_frame>Day 21 up to Day 42</time_frame>
        <population>Neither subject in cohort A had day 42 tumor biopsy material available. For analysis of Cohort &quot;All Other Patients&quot; n = 6 due to either a day 21 biopsy missing or a missing day 42 biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Concentration and Number of CD8+ Cells Infiltrating Tumor by IHC by Normalization of Kyn/Trp Ratios in Combination With MELITAC 12.1</title>
          <description>Immunohistochemistry: Tumors (day 21 &amp; day 42) were assessed by IHC for pattern of T-cell distribution and infiltration of cells expressing CD3 and CD8.</description>
          <population>Neither subject in cohort A had day 42 tumor biopsy material available. For analysis of Cohort &quot;All Other Patients&quot; n = 6 due to either a day 21 biopsy missing or a missing day 42 biopsy.</population>
          <units>Mean Ratio: Day42CD8s/Day21CD8s</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.9" lower_limit="0.5" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PBMC Transcriptome_v2</title>
        <description>Analysis of PBMC gene signature. This may be compared to immunologic response, tumor biopsy data and clinical response</description>
        <time_frame>Baseline to up to 16 week</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PBMC Transcriptome_v2</title>
          <description>Analysis of PBMC gene signature. This may be compared to immunologic response, tumor biopsy data and clinical response</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Number and Character of PBMC Populations, Including T and NK Cells, as Evaluated by Multiparameter Flow Cytometry_v2</title>
        <time_frame>Baseline to up to 1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number and Character of PBMC Populations, Including T and NK Cells, as Evaluated by Multiparameter Flow Cytometry_v2</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Expression of IDO1 Protein by IHC in Tumor or Tumor-infiltrating Cells_v2</title>
        <time_frame>Baseline to up to 16 weeks</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Expression of IDO1 Protein by IHC in Tumor or Tumor-infiltrating Cells_v2</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Level or Character of the Vaccine-induced CD8+ and CD4+ Specific T-cell Immune Responses by IFN-gamma ELISPOT_v2</title>
        <description>Assessment of immunologic response will be based on a fold-increase measure from baseline as well as using a positivity threshold</description>
        <time_frame>Baseline to up to 16 weeks</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Level or Character of the Vaccine-induced CD8+ and CD4+ Specific T-cell Immune Responses by IFN-gamma ELISPOT_v2</title>
          <description>Assessment of immunologic response will be based on a fold-increase measure from baseline as well as using a positivity threshold</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0_v2</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0_v2</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate Using the RECIST or Immune-Related Response Criteria (irRC)_v2</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate Using the RECIST or Immune-Related Response Criteria (irRC)_v2</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival_v2</title>
        <time_frame>From the time measurement criteria are met for complete response or partial response until the first date that recurrent and progressive disease is objectively documented, assessed up to 1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival_v2</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression Using RECIST or irRC_v2</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Pts.enrolled &gt;6 wks after failing anti-PD-1/PDL-1&#xD;
Pts will receive 300mg INCB024360 p.o. bid continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Pts.enrolled 2-6 wks after failing anti-PD-1/PDL-1&#xD;
Pts. receive 100 mg po bid INCB024360 continuous for 98 days + MELITAC 12.1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
          <group group_id="O3">
            <title>All Other Patients</title>
            <description>All advanced melanoma patients not previously treated with anti-PD-1 &amp; anti-PD-L1 who meet protocol entry criteria&#xD;
Pts. will receive 300 mg INCB024360 po bid for 98 days + MELITAC 12. 1 vaccine on days 21, 28, 35, 56, 77 &amp; 98</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression Using RECIST or irRC_v2</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from initiation of therapy through study post-treatment follow-up assessments, an average of one year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort A</title>
          <description>Pts. enrolled &gt;6 wks after failing anti-PD-1/PDL-1</description>
        </group>
        <group group_id="E2">
          <title>Cohort B</title>
          <description>Pts. enrolled 2-6 wks after failing anti-PD-1/PDL-1</description>
        </group>
        <group group_id="E3">
          <title>All Other Patients</title>
          <description>Pts. enrolled who have not been treated with check point inhibition&#xD;
100 mg INCB024360 po bid continuous for 98 days&#xD;
MELITAC 12.1 intradermal/subcutaneous on days 21, 28, 35, 56, 77, 98&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>flu like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>cytokine release syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>left eyelid stye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Investigations - Other,</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypophospatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>numbness in leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vasovagal reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>rash maculopapular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Martin A. Cheever</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-4141</phone>
      <email>mcheever@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

